1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Does estimated cardiorespiratory fitness accurately predict directly measured Vo(2peak) in breast cancer survivors?
    Meeting Abstract

    Michalski, M.; Capaci, C.; Rowed, K.; Happel, R.; Scott, J.
    Medicine and Science in Sports and Exercise (2018)

    Fulltext@MSK | Save
  • Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity
    Meeting Abstract

    Smith, M.; Littmann, E. R.; Slingerland, J. B.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Schluter, J.; Park, J. H.; O'Cearbhaill, R.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Burden and impact of geriatric syndromes associated with allogeneic hematopoietic cell transplantation in older adults
    Meeting Abstract

    Lin, R. J.; Elko, T. A.; Hilden, P.; Dahi, P. B.; Jakubowski, A. A.; Perales, M. A.; Barker, J.; Castro-Malaspina, H. R.; Shaffer, B. C.; Shahrokni, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Large-scale linkage analysis of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) families
    Meeting Abstract

    Clay-Gilmour, A. I.; Camp, N. J.; Wei, X.; Norman, A. D.; Sinnwell, J. P.; Demangel, D.; Waller, R. G.; Dumontet, C.; McKay, J.; Offit, K.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Yau, T.; Merle, P.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Harris, W. P.; Banu, E.; Sarker, D.; Tan, B.; van Vlierberghe, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)
    Meeting Abstract

    Shitara, K.; Tabernero, J.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data
    Meeting Abstract

    Sakai, H.; Felip, E.; Cortot, A. B.; Veillon, R.; Griesinger, F.; Patel, J.; Horn, L.; Mazieres, J.; De Castro Carpeno, J.; Morise, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Friedlander, M.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp): A phase II trial in progress
    Meeting Abstract

    Paik, P.; Sakai, H.; Bruns, R.; Scheele, J.; Straub, J.; Felip, E.
    Annals of Oncology (2018)

    Fulltext@MSK | Save